Aktueller Stand und Trends in der Epilepsietherapie bei Hund und Katze

H. Potschka; H. A. Volk; A. Pekcec

doi:10.1055/s-0038-1622788

Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, Table of Contents

Tierarztl Prax Ausg K Kleintiere Heimtiere 2009; 37(03): 211-217
DOI: 10.1055/s-0038-1622788

Für Studium und Praxis

Schattauer GmbH

Aktueller Stand und Trends in der Epilepsietherapie bei Hund und Katze

H. Potschka

¹Veterinärwissenschaftliches Department, Institut für Pharmakologie, Toxikologie und Pharmazie (Lehrstuhl: Prof. Dr. H. Potschka), Tierärztliche Fakultät, Ludwig-MaximiliansUniversität München

,

H. A. Volk

²Department of Veterinary Clinical Sciences, Royal Veterinary College, Hatfield, United Kingdom

,

A. Pekcec

¹Veterinärwissenschaftliches Department, Institut für Pharmakologie, Toxikologie und Pharmazie (Lehrstuhl: Prof. Dr. H. Potschka), Tierärztliche Fakultät, Ludwig-MaximiliansUniversität München

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Adusumalli VE, Gilchrist JR, Wichmann JK, Kucharczyk N, Sofia RD. Pharmacokinetics of felbamate in pediatric and adult beagle dogs. Epilepsia 1992; 33 (05) 955-960
2 Bailey KS, Dewey CW, Boothe DM, Barone G, Kortz GD. Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. J Am Vet Med Assoc 2008; 15 232 (06) 867-872
3 Boothe DM, George KL, Couch P. Disposition and clinical use of bromide in cats. J Am Vet Med Assoc. 2002; 15 221 (08) 1131-1135
4 Boothe DM, Perkins J, Dewey C. Clinical pharmacokinetics and safety of the anticonvulsant zonisamide in healthy dogs following single and multiple dosing. J Vet Intern Med 2005; 19 (03) 421
5 Center SA, Elston TH, Rowland PH, Rosen DK, Reitz BL, Brunt JE, Rodan I, House J, Bank S, Lynch LR, Dring LA, Levy JK. Fulminant hepatic failure associated with oral administration of diazepam in 11 cats. J Am Vet Med Assoc 1996; 209 (03) 618-625
6 Dayrell-Hart B, Tiches D, Vite C et al. Efficacy and safety of felbamate as an anticonvulsant in dogs with refractory seizures. J Vet Intern Med 1996; 10 (03) 174
7 Dewey CW, Guiliano R, Boothe DM, Berg JM, Kortz GD, Joseph RJ, Budsberg SC. Zonisamide therapy for refractory idiopathic epilepsy in dogs. J Am Anim Hosp Assoc 2004; 40 (04) 285-291
8 Dewey CW, Barone G, Boothe DM et al. The use of oral levetiracetam as an add-on anticonvulsant drug in cats receiving Phenobarbital. J Vet Intern Med 2005; 19 (03) 458
9 Frey HH, Schwartz-Porsche D. Pharmakologische Grundlagen der Behand-lung der Epilepsie bei Hund und Katze. Tierärztl Prax 1985; 13: 541-549
10 Frey HH, Löscher W. Hrsg. Lehrbuch der Pharmakologie und Toxikologie fär die Veterinärmedizin. Stuttgart: Enke; 2002
11 Fröscher W, Vasella F, Hufnagel A. Hrsg. Die Epilepsien. Grundlagen – Klinik – Behandlung. Stuttgart: Schattauer; 2004
12 Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol 2006; 24 536 (1-2) 102-108
13 Govendir M, Perkins M, Malik R. Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. Aust Vet J 2005; 83 (10) 602-608
14 Harden C. Safety profile of levetiracetam. Epilepsia 2001; 42 (Suppl. 04) Suppl 36-39
15 Hasegawa D, Kobayashi M, Kuwabara T, Ohmura T, Fujita M, Orima H. Pharmacokinetics and toxicity of zonisamide in cats. J Feline Med Surg 2008; 10 (04) 418-421
16 Jaggy A, Steffen F. Epileptische Krampfanfälle beim Hund. Teil III: Intrazerebrale Ursachen, idiopathische Epilepsie und Therapie. Prakt Tierarzt 1995; 4: 304-314
17 Kantrowitz LB, Peterson ME, Trepanier LA, Melián C, Nichols R. Serum total thyroxine, total triiodothyronine, free thyroxine, and thyrotropin concentrations in epileptic dogs treated with anticonvulsants. J Am Vet Med Assoc 1999; 15 214 (12) 1804-1808
18 Kwan P, Brodie MJ. Refractory epilepsy: a progressive, intractable but preventable condition?. Seizure 2002; 11 (02) 77-84
19 Löscher W. Pharmakologische Grundlagen zur Behandlung von Epilepsie bei Hund und Katze. Prakt Tierarzt 2003; 84: 574-586
20 Löscher W, Potschka H, Rieck S, Tipold A, Rundfeldt C. Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Epilepsia 2004; 45 (010) 1228-1239
21 Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the anti-epileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 29 101 (026) 9861-9866
22 Orito K, Saito M, Fukunaga K, Matsuo E, Takikawa S, Muto M, Mishima K, Egashira N, Fujiwara M. Pharmacokinetics of zonisamide and drug interaction with phenobarbital in dogs. J Vet Pharmacol Ther 2008; 31 (03) 259-264
23 Platt S, Olby N. BSAVA Manual of Canine and Feline Neurology. West Sussex. John Wiley and Sons; 2004
24 Platt SR, Adams V, Garosi LS, Abramson CJ, Penderis J, De Stefani A, Matiasek L. Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy. Vet Rec 2006; 23 (30) 159 (026) 881-884
25 Riek S, Löscher W, Rundfedt C, Tipold A. Wirkung verschiedener antiepileptischer Substanzen beim Hund. Tierärztl Prax 2002; 3 K 92
26 Ruehlmann D, Podell M, March P. Treatment of partial seizures and seizure-like activity with felbamate in six dogs. J Small Anim Pract 2001; 42 (08) 403-408
27 Schwartz-Porsche D, Löscher W, Frey HH. Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. J Vet Pharmacol Ther 1985; 8 (02) 113-119
28 Schwartz-Porsche D, Järgens U. Wirksamkeit von Bromid bei den therapieresistenten Epilepsien des Hundes. Tierärztl Prax 1991; 19: 395-401
29 Steinberg M, Faissler D. Levetiracetam therapy for longterm idiopathic epileptic dogs. In Proceedings of the 22nd Annual American College of Veteri -nary Internal Medicine Forum. 2004
30 Trepanier LA, Van Schoick A, Schwark WS, Carrillo J. Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases 1992–1996. J Am Vet Med Assoc 1998; 15 213 (10) 1449-1453
31 Volk HA, Chandler KE, Cappello R, Cherubini GB. New insights into efficacy and side effects of potassium bromide in epileptic cats. J Vet Int Med 2006; 20: 780
32 Volk HA, Matiasek LA, Feliu-Pascual AL, Platt SR, Chandler KE. The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. Vet J 2007; 176 (03) 310-319
33 von Klopmann T, Rambeck B, Tipold A. Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. J Small Anim Pract 2007; 48 (03) 134-138
34 Wagner SO. Lower airway disease in cats on bromide therapy for seizures. Proceedings, 19th Am Coll Vet Intern Med Forum. 2001: 562
35 Weiss KL, Schroeder CE, Kastin SJ, Gibson JP, Yarrington JT, Heydorn WE, McBride RG, Sussman NM, Arezzo JC. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology 1994; 44 (10) 1944-1949
36 Wong IC, Lhatoo SD. Adverse reactions to new anticonvulsant drugs. Drug Saf 2000; 23 (01) 35-56